QuidelOrtho Corp highlights diagnostics portfolio as investors track Nasdaq listing
QuidelOrtho Corp, a global provider of in vitro diagnostics solutions, is listed on Nasdaq, offering US investors direct exposure to its testing platforms. The company, formed from the merger of legacy Quidel and Ortho businesses, operates across clinical laboratories and point-of-care settings, with a business model focused on instrument placement and recurring revenue from test kits and reagents. Its financial performance is tied to test volumes and broader healthcare activity, including demand for routine diagnostics and infectious disease screening.
Enterprise value to revenue forward of QuidelOrtho Corporation – BOATS:QDEL
The article presents the enterprise value to revenue forward for QuidelOrtho Corporation (QDEL). It is a financial snippet provided by TradingView, detailing general information about the company's financial data on the Blue Ocean Alternative Trade System.
Enterprise value to EBIT forward of QuidelOrtho Corporation – NASDAQ:QDEL
This article provides financial data for QuidelOrtho Corporation (NASDAQ: QDEL), specifically focusing on its enterprise value to EBIT forward. It indicates no live trades as the market is closed, and lists various features and services offered by TradingView, the platform displaying this information.
QuidelOrtho (QDEL) Moves 32.2% Higher: Will This Strength Last?
QuidelOrtho (QDEL) shares surged 32.2% after reports indicated the company is exploring the sale of its Point-of-Care testing business for an estimated $1.5 billion to reduce its $2.6 billion debt. While this move is seen as a potential value-unlocking catalyst, the stock currently holds a Zacks Rank #3 (Hold), and its near-term strength depends on future earnings estimate revisions. Investors are advised to monitor QDEL for sustained performance.
Enterprise value to EBIT forward of QuidelOrtho Corporation – BOATS:QDEL
This article focuses on the enterprise value to EBIT forward for QuidelOrtho Corporation (QDEL), as presented on the TradingView platform. It highlights financial data and tools available for analyzing this medical technology stock. The content appears to be a truncated snippet from a financial data display page.
Does QuidelOrtho's (QDEL) Index Exit and New CFO Hint at a Shift in Growth Identity?
QuidelOrtho (QDEL) was recently removed from several Russell growth indexes and appointed Micah Young as its new CFO, signaling a potential shift in its investment narrative. These changes occur as the company faces shrinking COVID testing revenues and ongoing unprofitability. The article suggests investors should reassess QuidelOrtho's risk profile and focus on its ability to stabilize revenues and restore margins.
Enterprise value to revenue forward of QuidelOrtho Corporation – NASDAQ:QDEL
This article provides financial information for QuidelOrtho Corporation (NASDAQ: QDEL), specifically focusing on its enterprise value to revenue forward. It appears to be a snapshot of financial data available on TradingView, listing the company's ticker, market, and offering a general overview of its financials.
QuidelOrtho (QDEL) director receives 15,532 restricted stock units as equity award
QuidelOrtho director R. Scott Huennekens was granted 15,532 restricted stock units (RSUs) as an equity award, representing the right to receive an equal number of QuidelOrtho common shares. These RSUs will vest on June 25, 2027, and currently, Huennekens directly holds this amount. This transaction is considered an equity compensation rather than a market purchase.
Jefferies on QuidelOrtho (QDEL): 'we view a potential sale as a net positive'
Jefferies analyst Tycho Peterson reiterated a Hold rating and $12.50 price target on QuidelOrtho (QDEL). The analyst views a potential sale of the company as a "net positive," though further details were behind a premium paywall.
QDEL Stock Eyes Best Day In Over A Year — Point-Of-Care Sale Talks Ignite Rally
QuidelOrtho (QDEL) shares surged by 35% on news that it is exploring the sale of its point-of-care testing unit for approximately $1.5 billion. This potential divestiture aims to address the company's significant $2.6 billion net debt, which largely resulted from its 2022 combination of Quidel Corporation and Ortho Clinical Diagnostics. Private equity firms like Advent International, SK Capital Partners, and Archimed have reportedly expressed interest in the business, which includes rapid antigen tests for COVID and flu.
QDEL Stock Eyes Best Day In Over A Year — Point-Of-Care Sale Talks Ignite Rally
QuidelOrtho's shares (QDEL) surged 35% following reports that the company is exploring the sale of its point-of-care testing business for approximately $1.5 billion. This potential divestiture aims to address the company's substantial $2.6 billion net debt. Private equity firms Advent International, SK Capital Partners, and Archimed have reportedly expressed interest in the segment, which includes the rapid antigen tests approved during the Covid pandemic.
QuidelOrtho Corporation(NasdaqGS: QDEL) dropped from Russell 3000 Growth Benchmark
QuidelOrtho Corporation (NasdaqGS: QDEL) has been removed from the Russell 3000 Growth Benchmark. This news follows several other recent developments for the company, including the appointment of Micah Young as Principal Financial Officer, scheduled for July 6, 2026, and recent adjustments to price targets by UBS and Jefferies, as well as their Q1 2026 earnings report. The company specializes in in vitro diagnostics, manufacturing intelligent solutions across immunoassay, molecular testing, clinical chemistry, and transfusion medicine.
Price to earnings forward of QuidelOrtho Corporation – BIVA:QDEL1
This article provides financial information for QuidelOrtho Corporation under the stock symbol BIVA:QDEL1. It specifically focuses on the company's price to earnings forward metric. The content appears to be a financial data page from TradingView.
Price to sales forward of QuidelOrtho Corporation – BIVA:QDEL1
This article provides a brief snapshot of QuidelOrtho Corporation's (BIVA:QDEL1) "Price to Sales Forward" metric. The content appears to be from a financial data platform, showing basic company information and a section for this specific financial ratio. The market status indicates it's currently closed with no trades.
Price to book forward of QuidelOrtho Corporation – NASDAQ:QDEL
This article displays the "Price to book forward" financial metric for QuidelOrtho Corporation (NASDAQ: QDEL) as presented on TradingView. It shows the period, value, change, and percentage change for this specific financial ratio, indicating it was made by humans. The content is primarily a listing of data and structural information from the TradingView platform.
Diagnostics Firm QuidelOrtho Looks at Testing Unit Sale, Says FT
Diagnostics firm QuidelOrtho Corp is reportedly considering selling its point-of-care testing unit for an estimated $1.5 billion. The Financial Times indicates that several private equity firms, including Advent International, SK Capital Partners, and Archimed, have shown interest in acquiring the asset.
Price to earnings forward of QuidelOrtho Corporation – NASDAQ:QDEL
This article displays the "Price to earnings forward" financial metric for QuidelOrtho Corporation (NASDAQ: QDEL). It shows that as of "Period," the value for this metric is "Value" with a "Change" and "Change %." The data is provided by ICE Data Services and FactSet.
QL1A Forecast — Price Target — Prediction for 2027
This article provides a forecast for QuidelOrtho Corporation (QL1A) stock on the Dusseldorf Stock Exchange for 2027, including analyst price targets and ratings. It details the company's financial performance, such as recent earnings and revenue, and addresses frequently asked questions about the stock, its ticker, and historical price movements. The report also mentions the company's employee count and EBITDA.
Enterprise value to EBITDA forward of QuidelOrtho Corporation – BIVA:QDEL1
This article displays the "Enterprise value to EBITDA forward" for QuidelOrtho Corporation (BIVA:QDEL1). It presents financial data for the company on the TradingView platform, noting that the market is closed and there have been no trades. The page is primarily a data display with extensive navigation and copyright information.
QDEL Forecast — Price Target — Prediction for 2027
This article provides a detailed forecast for QuidelOrtho Corporation (QDEL) stock, including analyst price targets, historical performance, and financial metrics. It highlights that analysts predict a max estimate of $38.00 and a min estimate of $11.00 for QDEL's future price. The current stock price is $14.03, showing recent increases but a significant annual decrease.
QuidelOrtho Appoints Micah Young as Chief Financial Officer
QuidelOrtho Corporation has appointed Micah Young as its new Chief Financial Officer, effective July 6, 2026. Young, who previously served as CFO at Masimo Corporation, brings over two decades of financial leadership in the medical technology sector. He succeeds Joseph M. Busky, who is retiring but will serve in an advisory role for a smooth transition.
QuidelOrtho names Micah Young as chief financial officer
QuidelOrtho Corporation has appointed Micah Young as its new Chief Financial Officer, effective July 6, 2026, succeeding Joseph M. Busky. Young previously served as CFO of Masimo Corporation and brings significant medical technology and finance experience. The appointment comes as QuidelOrtho faces financial challenges, including negative free cash flow and a substantial debt load, with the stock currently considered undervalued according to InvestingPro analysis, following a recent downgrade by Jefferies due to disappointing Q1 2026 results.
QuidelOrtho names Micah Young as chief financial officer
QuidelOrtho Corporation has appointed Micah Young as its new Chief Financial Officer, effective July 6, 2026. Young, previously CFO at Masimo Corporation, will succeed Joseph M. Busky amidst financial challenges for QuidelOrtho, including negative free cash flow and a significant debt load. The company recently reported disappointing Q1 2026 earnings and a downgrade from Jefferies, highlighting the importance of Young's leadership in improving profitability and shareholder value.
QuidelOrtho Names Micah Young Chief Financial Officer
QuidelOrtho Corporation has appointed Micah Young as Chief Financial Officer, effective July 6, 2026. Young, who previously served as EVP and CFO at Masimo Corporation, will focus on improving profitability, strengthening cash generation, and driving long-term shareholder value. He succeeds Joseph M. Busky, who will remain in an advisory role during the transition.
QuidelOrtho Appoints Micah Young as Chief Financial Officer
QuidelOrtho Corporation has appointed Micah Young as its new Chief Financial Officer, effective July 6, 2026. Young, who previously served as CFO at Masimo Corporation, brings over two decades of financial leadership experience in the medical technology sector. He succeeds Joseph M. Busky and will focus on improving profitability, enhancing cash generation, and strengthening operational discipline for QuidelOrtho.
QuidelOrtho Appoints Micah Young as Chief Financial Officer
QuidelOrtho Corporation has announced the appointment of Micah Young as its new Chief Financial Officer, effective July 6, 2026. Young brings over two decades of experience in medical technology finance, having previously served as CFO of Masimo Corporation. He succeeds Joseph M. Busky, who is retiring but will assist in the transition, as QuidelOrtho aims to improve profitability, enhance cash generation, and create shareholder value.
Micah Young becomes QuidelOrtho (NASDAQ: QDEL) CFO as Busky shifts to advisor
QuidelOrtho Corporation has appointed Micah Young as its new Chief Financial Officer, effective July 6, 2026, replacing the retiring Joseph M. Busky, who will transition to an advisory role. Young, previously CFO of Masimo Corporation, will receive an annual base salary of $750,000, a 100% target cash bonus, a $500,000 cash sign-on bonus, and $6,500,000 in restricted stock units, with additional equity grants expected in 2027. Busky will receive a reduced salary during his transition and advisory period.
QuidelOrtho Corp (QDEL) Earnings Forecast: Future EPS & Revenue Growth Estimates
QuidelOrtho Corp (QDEL) has an earnings forecast score of 6.00, ranking 172nd in its industry, with an average price target of $32.00 from 5 analysts. Analysts forecast QDEL's next quarter revenue at $621.56M and an EPS of -$0.03, following a previous quarter EPS of -$1.92. The overall analyst rating for QDEL is "Hold."
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
QuidelOrtho (QDEL) is positioned for growth due to its strong product portfolio and cost-saving initiatives, despite recent stock declines and overreliance on the respiratory business. The company's diversified diagnostic portfolio and strategic expansions, alongside improvements in operational efficiency, are expected to drive future performance. However, fluctuating demand in the respiratory segment remains a significant risk factor for its revenues and profitability.
QuidelOrtho (QDEL) shareholders approve board slate, say-on-pay and KPMG
QuidelOrtho Corporation (QDEL) shareholders approved all management proposals at their 2026 Annual Meeting. This included the election of all ten director nominees, advisory approval of the compensation for named executive officers, and the ratification of KPMG LLP as the independent registered public accounting firm for the 2026 fiscal year. All proposals garnered strong support from stockholders.
Is the Options Market Predicting a Spike in QuidelOrtho Stock?
The options market is showing high implied volatility for QuidelOrtho (QDEL) stock, specifically for the June 18, 2026 $37.50 Call, suggesting investors anticipate a significant price movement. Despite this, analysts currently rate QuidelOrtho as a "Strong Sell" with downward revisions in earnings estimates, indicating a potential divergence between market sentiment and fundamental analysis. Options traders might use this high implied volatility to sell premiums, banking on the stock not moving as much as expected.
QuidelOrtho (NASDAQ: QDEL) director gains 2,156 shares via RSU release
QuidelOrtho (NASDAQ: QDEL) director Kenneth F. Buechler increased his direct stake by 2,156 common shares through the release and conversion of restricted stock units (RSUs) on June 6, 2026. These shares were granted at $0.00 each as part of the company's deferred compensation program for non-employee directors. Following these transactions, Buechler directly owns 110,906 common shares of QuidelOrtho.
QuidelOrtho (QDEL) director settles 973 RSUs into common stock award
QuidelOrtho Corp director Mary Lake Polan, Ph.D., converted 973 restricted stock units (RSUs) into common stock on June 6, 2026, as part of the company's deferred compensation program for non-employee directors. These transactions, previously reported awards, were settled at $0.00 per unit, increasing her direct holdings to 20,442 common shares and indirect holdings to 17,353 shares through an LLC. The activity is categorized as routine equity compensation rather than open-market trading.
QuidelOrtho (QDEL) director receives 1,183 shares from restricted stock unit release
QuidelOrtho (QDEL) director Kenneth J. Widder acquired 1,183 common shares on June 6, 2026, through the release and conversion of previously granted restricted stock units. This transaction, reported via a Form 4 filing, is a routine equity compensation activity and not an open-market trade. The shares were released as part of QuidelOrtho's deferred compensation program for non-employee directors, following an elected deferral schedule.
QuidelOrtho Corp (QDEL) director gains 1,252 shares from RSU release
QuidelOrtho Corp director Michael Edward L. acquired 1,252 common shares on June 6, 2026, through the release and conversion of restricted stock units (RSUs) as part of his director compensation. These shares were awarded at $0.00 per share, and following the transaction, he directly holds approximately 29,433 common shares. The RSUs were previously reported and their release was deferred under the company's non-employee director deferred compensation program.
QuidelOrtho Corporation - Common Stock (NQ: QDEL
This page provides recent news and financial updates for QuidelOrtho Corporation (QDEL). It covers announcements regarding company leadership, quarterly financial results, investor events, and mentions from financial analysts and news outlets regarding stock performance and sector insights. The article also touches on broader healthcare sector topics like value stocks, growth stocks, and COVID-19 related news.
QuidelOrtho and Allo Hope Foundation partner to advance prenatal care for maternal alloimmunization
QuidelOrtho and the Allo Hope Foundation have announced a partnership to improve prenatal care for maternal alloimmunization, a condition that can lead to hemolytic disease of the fetus and newborn (HDFN). The collaboration will focus on developing educational resources for healthcare providers and families, promoting early testing, and enhancing access to care, especially for underserved communities. Their joint efforts aim to provide accurate information and compassionate support to improve outcomes for affected families.
Assessing QuidelOrtho (QDEL) Valuation After A Sharp One Month Share Price Rebound
QuidelOrtho (QDEL) has seen a 31% share price rebound recently, though its long-term performance remains negative. Analysts suggest the stock is undervalued with a fair value of $34.67, driven by expected earnings recovery and growth in high-value diagnostic solutions, despite ongoing risks like weak post-pandemic COVID testing demand. The article encourages investors to analyze both rewards and risks before making investment decisions.
QDEL Stock Slumps On Mixed Wall Street Price Target Revisions After Q4 Report
Shares of QuidelOrtho Corporation (QDEL) dropped 22% after its Q4 earnings report and mixed 2026 guidance, leading to varied price target revisions from Wall Street analysts. While the company's Q4 revenue and adjusted EPS beat estimates, its free cash flow forecast for 2026 fell significantly below expectations. Analysts like UBS lowered their price targets due to the mixed guidance and focus on free cash flow, however, JPMorgan and Citi raised their targets despite an "Underweight" and "Neutral" rating respectively.
QuidelOrtho (QDEL) Up 24.1% Since Last Earnings Report: Can It Continue?
Shares of QuidelOrtho (QDEL) have increased by 24.1% since its last earnings report, outperforming the S&P 500. Despite this, the company's first-quarter 2026 adjusted loss per share and revenues were below last year's figures, though revenue did surpass the Zacks Consensus Estimate. Analyst estimates for the stock have trended downward, leading to a Zacks Rank #5 (Strong Sell).
QuidelOrtho's Respiratory Exposure Remains a Key Near-Term Risk
QuidelOrtho (QDEL) faces significant near-term risk due to its high exposure to respiratory testing, as evidenced by a substantial decline in first-quarter 2026 revenue and adjusted loss per share attributed to a milder respiratory season. Despite stable market share, reduced demand severely impacted financial performance. The company's profitability and cash flow remain sensitive to respiratory demand fluctuations, differentiating it from more diversified peers like Abbott Laboratories and Thermo Fisher Scientific.
QuidelOrtho Corporation (QDEL) Presents at 46th Annual William Blair Growth Stock Conference - Slideshow
QuidelOrtho Corporation (QDEL) presented a slideshow at the 46th Annual William Blair Growth Stock Conference on June 3, 2026. Seeking Alpha's transcripts team published the slide deck in conjunction with the event. This article makes the presentation materials available to readers.
QuidelOrtho (QDEL) director RSUs vest into 6,829 shares, holding 19,469 directly
QuidelOrtho Corp director Mary Lake Polan, Ph.D., reported that 6,829 restricted stock units (RSUs) vested on May 29, 2026, converting into common stock at a $0.00 conversion price. Following this transaction, Polan directly holds 19,469 shares of QuidelOrtho common stock, with an additional 17,353 shares held indirectly through an LLC. This activity was detailed in a Form 4 SEC filing, indicating routine equity compensation.
QuidelOrtho (QDEL) director Ann D. Rhoads receives 6,829 shares as RSUs vest
QuidelOrtho (QDEL) director Ann D. Rhoads received 6,829 shares of common stock as restricted stock units (RSUs) vested on May 29, 2026. These RSUs were converted into common shares at no cost, which is a routine compensation event. Following this transaction, Rhoads directly holds 23,257 shares of QuidelOrtho common stock.
QuidelOrtho (QDEL) director adds 6,829 shares through RSU vesting
QuidelOrtho Corp director Kenneth F. Buechler received 6,829 shares of common stock on May 29, 2026, due to the vesting of restricted stock units (RSUs). These RSUs converted into shares at no exercise price, and Buechler now directly holds 108,750 shares of QuidelOrtho common stock. This transaction is classified as neutral in terms of impact and sentiment.
Director at QuidelOrtho (QDEL) gains 6,829 shares through RSU vesting
QuidelOrtho director Kenneth J. Widder acquired 6,829 shares of the company's common stock through the vesting of restricted stock units (RSUs) on May 29, 2026. This transaction increased his direct holdings to 43,890 shares. The Form 4 filing indicates this was a compensation-related grant rather than a market purchase.
QuidelOrtho (QDEL) director adds 6,829 shares via RSU vesting
Matthew Strobeck, a director at QuidelOrtho (QDEL), increased his direct ownership by 6,829 shares after restricted stock units (RSUs) vested on May 29, 2026. These RSUs converted into common stock at $0.00 per share, bringing his direct holdings to 34,604 common shares. The filing also detailed his indirect holdings, including shares in Birchview Fund, LLC and UGMA accounts for his children, clarifying beneficial ownership.
QuidelOrtho (QDEL) director gains 6,829 shares as RSUs vest
John R. Chiminski, a director at QuidelOrtho (QDEL), acquired 6,829 shares of common stock following the vesting of restricted stock units on May 29, 2026. This transaction was part of a previously reported equity compensation award. After this, Chiminski directly holds 9,352 shares of QuidelOrtho Common Stock.
QuidelOrtho Corp (QDEL) director awarded 6,829 shares in equity grant
QuidelOrtho Corp director Joseph D. Wilkins Jr. received an equity grant of 6,829 shares of common stock on May 29, 2026, stemming from the vesting of previously granted restricted stock units. Following this transaction, Wilkins Jr. directly holds 18,705 shares of QuidelOrtho common stock, with no sales reported in connection with this filing. The shares were acquired at an exercise price of $0.00 per share as part of two reported acquisition transactions.
QuidelOrtho and Allo Hope Foundation Join Forces to Advance Education, Connection and Early Testing for Alloimmunized Pregnancies
QuidelOrtho and the Allo Hope Foundation have announced a collaboration to improve prenatal care for alloimmunized pregnancies. This partnership will focus on increasing education, facilitating early testing, and strengthening connections between healthcare providers and patients affected by maternal red blood cell alloimmunization, which can cause hemolytic disease of the fetus and newborn (HDFN). The initiative aims to provide timely information and support, particularly for underserved populations, by developing co-produced educational materials.
